PALO ALTO, Calif., Nov. 8, 2019 /PRNewswire/ -- Kodiak Sciences
Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases, today announced that it will
report third quarter 2019 results on Tuesday, November 12, 2019. Following the
release of results, Kodiak will host a business highlights webcast
at 2:00 p.m. Pacific Time.
Kodiak management will provide regulatory updates on the
company's "2022 Vision" and announce interim data from its on-going
Phase 1b clinical study of KSI-301,
as well as other business highlights for the third quarter ended
September 30, 2019.
A live webcast of the presentation will be available on the
"Investors & Media" section of Kodiak's website at
http://ir.kodiak.com/ and will remain available for replay
following the event.
About KSI-301
KSI-301 is an investigational therapy built on Kodiak's
proprietary Antibody Biopolymer Conjugate (ABC) Platform and is
designed to maintain potent and effective drug levels in ocular
tissues for longer than existing approved agents. Kodiak's
objective with KSI-301 is to develop a new first-line agent to
improve outcomes for patients with retinal vascular diseases and to
enable earlier treatment and prevention of vision loss for patients
with diabetic eye disease. KSI-301 is being developed and is fully
owned globally by Kodiak.
About Kodiak Sciences Inc.
Kodiak™ is a clinical stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases. We are focused on bringing new
science to the design and manufacture of next generation retinal
medicines to prevent and treat the leading causes of blindness
globally. Our ABC Platform™ merges the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including age-related
macular degeneration and diabetic eye diseases. Kodiak has
leveraged its ABC Platform to build a pipeline of product
candidates in various stages of development including KSI-501, our
bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of
neovascular retinal diseases with an inflammatory component, and
including new triplet inhibitors for dry AMD and glaucoma. Kodiak
is based in Palo Alto, CA. For
more information, visit www.kodiak.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include, but are not limited to,
statements regarding our platform technology and potential
therapies, future development plans, clinical and regulatory
objectives and the timing thereof, anticipated design of planned
clinical trials and our ability to advance our product candidates
into later stages of development. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as "may," "will," "should," "would," "expect," "plan,"
"believe," "intend," "pursue," and other similar expressions among
others. Any forward-looking statements are based on management's
current expectations of future events and are subject to a number
of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied
by such forward-looking statements. These risks and uncertainties
discussed in our filings with the Securities and Exchange
Commission. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual
results to differ from those contained in the forward-looking
statements, see the section entitled "Risk Factors" in our most
recent Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof and
Kodiak undertakes no obligation to update forward-looking
statements, and readers are cautioned not to place undue reliance
on such forward-looking statements.
"Kodiak," "ABC Platform" and the Kodiak logo are registered
trademarks or trademarks of Kodiak Sciences Inc. in various
jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-to-report-third-quarter-2019-results-and-host-business-highlights-webcast-on-november-12-2019-300954623.html
SOURCE Kodiak Sciences Inc.